Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cladribine
Drug ID BADD_D00479
Description An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Indications and Usage For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Marketing Status approved; investigational
ATC Code L01BB04; L04AA40
DrugBank ID DB00242
KEGG ID D01370
MeSH ID D017338
PubChem ID 20279
TTD Drug ID D05GJW
NDC Product Code 42658-010; 12502-5406; 0143-9871; 44087-4000; 54893-0115; 76055-0051; 63323-140; 59605-3006; 65129-1260; 76055-0052; 12502-4912; 58623-0037
UNII 47M74X9YT5
Synonyms Cladribine | 2-Chlorodeoxyadenosine | 2-Chloro-2'-deoxyadenosine | 2'-Deoxy-2-chloroadenosine | Leustatin
Chemical Information
Molecular Formula C10H12ClN5O3
CAS Registry Number 4291-63-8
SMILES C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bacteraemia11.01.11.001--
Basal cell carcinoma23.08.02.001; 16.03.02.0010.000382%Not Available
Blepharitis23.03.04.012; 06.04.04.001--Not Available
Blister12.01.06.002; 23.03.01.0010.000780%Not Available
Blood bilirubin increased13.03.04.018--
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bone pain15.02.01.001--
Breast cancer21.05.01.003; 16.10.01.0010.000994%Not Available
Burning sensation17.02.06.001; 08.01.09.0290.000596%Not Available
Cachexia08.01.01.009; 16.32.03.011; 14.03.02.001--Not Available
Cardiac failure02.05.01.001--
Cardiac murmur13.14.01.001--Not Available
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Cervical dysplasia21.06.01.0020.000306%Not Available
Cervix carcinoma16.12.01.001; 21.06.02.0010.000229%Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.000978%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills08.01.09.001; 15.05.03.0160.001009%
Choking sensation22.12.03.004; 19.01.02.0020.000153%Not Available
Cholecystitis09.03.01.001--
Cholelithiasis09.03.01.0020.000153%Not Available
Chromaturia20.02.01.0020.000336%
Chronic myeloid leukaemia16.01.07.001; 01.10.07.0010.000153%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Cough22.02.03.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 12 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene